Lynn Seely
Vice President
Pharmaceutical
rovi guides inc
Canada
Biography
Lynn Seely has served as the Chief Executive Officer of Myovant since May 2016 where she also serves as President and Executive Director. Dr. Seely is an endocrinologist with over 20 years of drug development experience and biopharmaceutical company leadership. She served as Chief Medical Officer at Medivation from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego. Lynn Seely has served as the Chief Executive Officer of Myovant since May 2016 where she also serves as President and Executive Director. Dr. Seely is an endocrinologist with over 20 years of drug development experience and biopharmaceutical company leadership. She served as Chief Medical Officer at Medivation from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. Dr. Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
Research Interest
Pharmaceutical Analysis and Quality Assurance Industrial Pharmacy Clinical Pharmacy Pharmaceutical Administration Medicinal Chemistry Drug Discovery and Development